NCT03160261

Effect of Exenatide on Cortisol Secretion

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University of Tartu · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The primary aim of the study is to describe the effect of single dose of 10 micrograms (μg) exenatide given subcutaneously (s/c) on cortisol secretion. Secondary outcomes involve ACTH and glucose levels.

Detailed description

Exenatide is a short-acting Glucagon-Like Peptide receptor 1 (GLP-1 R) agonist. The clinical trial is conducted in10 healthy volunteers. Each subject receives one dose of subcutaneous exenatide (10 μg). After that, hormonal and physiological changes are measured during two hours. The blood samples are taken in 30-minute intervals. The primary endpoint is peak value of cortisol achieved during the 2 hours after drug administration.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Exenatide Injection	Single injection of Exenatide 10μg subcutaneously

Timeline

• Start date: 2017-09-07
• Primary completion: 2017-12-28
• Completion: 2017-12-28
• First posted: 2017-05-19
• Last updated: 2018-05-03

Locations

1 site across 1 country: Estonia